LungLife AI - PLA Code application submitted in first step in reimbursement process

October 12, 2021

12 October 2021

 

LungLife AI, Inc.
(the “Company” or “LungLife”) 

PLA Code application submitted in first step in reimbursement process

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer enhanced by artificial intelligence, announces it has submitted its application for a Proprietary Laboratory Analysis (PLA) code to the American Medical Association.

 

Reimbursement in the US is comprised of three components: code, price, and coverage. The code is the mechanism by which clinical laboratories can more specifically identify their tests when billing Medicare and commercial insurers. If LungLife’s application for a PLA code is granted, the code will be priced for Medicare by the Centers for Medicare & Medicaid Services (CMS) in 2022. PLA code applications can be made at four times in the year.

 

Click HERE for the full announcement.

Subscribe for Email Alerts

This field is for validation purposes and should be left unchanged.
© 2020 LungLIfe AI, Inc.
All rights reserved. LiquidBiopsy is a trademark of LungLife AI, Inc.
magnifiercrossmenuchevron-down